The vast majority of human disease is governed by the epigenome, the subtle machinery that controls the volume of gene expression in cells. Tune Therapeutics is pioneering the creation of epi-therapeutic medicines with its powerful and precise epigenomic control platform, TEMPO. Unlike genome editing, TEMPO dials the volume of gene expression up or down towards healthy levels, without breaking or permanently rewriting DNA – and it can do this in multiple genes at once. This genetic tuning approach allows us to change cell fate and function at will, unlocking the ability to reverse pathways of cancer, genetic disease and aging. Our approach effectively expands the potential reach of genetic medicine – from targeting a limited range of rare conditions, to overcoming thousands of complex and chronic diseases that currently have no curative treatment.
Location: United States, North Carolina, Durham
Employees: 11-50
Total raised: $175M
Founded date: 2020
Investors 4
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
| - | Biovision ... | biovision.... |
| - | WRF Capita... | wrfseattle... |
| - | Duke Capit... | dukecapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.01.2025 | Series B | $175M | - |
Mentions in press and media 11
| Date | Title | Description |
| 14.01.2025 | Tune Therapeutics: A New Era in Epigenome Editing | In the realm of biotechnology, innovation is the lifeblood. Tune Therapeutics, a Durham, North Carolina-based company, has just secured over $175 million in Series B funding. This significant investment is a beacon of hope for chronic disea... |
| 13.01.2025 | Tune Therapeutics Completes Over $175M in Series B Financing | Tune Therapeutics, a Durham, NC-based epigenome editing company, raised over $175M in Series B funding. The round was led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation. The company intends to use the f... |
| 13.01.2025 | Tune Therapeutics: Over $175 Million (Series B) Raised For Advancing Field-Leading Epigenome Editing Programs | Leading epigenome editing company Tune Therapeutics announced the completion of over $175 million in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures, and Hevolution Foundation. This funding will accelerate the devel... |
| 01.05.2024 | Tune Therapeutics to test vaccine-like epigenetics platform | Duke University spinout Tune Therapeutics is rehearsing the overture of its avant-garde therapeutic platform targeting chronic Hepatitis B Virus (HBV) that could also upend many more chronic disease treatments. Tune, which is jointly based ... |
| 19.09.2023 | How Reed Jobs’ venture firm tackles cancer | Reed Jobs’ new venture firm can change the lives of the estimated 18.1 million diagnosed cancer patients worldwide. Yosemite, Jobs’ fund for cancer-fighting biotech, launched in August with $200 million in funding from investors like MIT, M... |
| 11.04.2023 | Tech Moves: Adaptive Biotechnologies COO departing; Sana adds leaders; and more | Mark Adams. (Adaptive Photo) — Mark Adams is stepping down as chief operating officer of Adaptive Biotechnologies, the company said today in a regulatory filing. Adams joined the Seattle-based biotech giant more than three years ago. The fi... |
| 10.04.2023 | Tech Moves: Halo leader departing; Remitly adds board directors; drone vet lands at Rantizo | Phyllis Campbell (left) and Ryno Blignaut. — Seattle-based fintech company Remitly added two new board members: Ryno Blignaut and Phyllis Campbell. Blignaut is an investor with Silicon Valley venture firm Khosla Ventures and previously serv... |
| 02.12.2021 | Tune Therapeutics launches with $40M in funding, aims to fine-tune activity of genes in cells | Tune CEO Matt Kane. (Tune Photo) A new biotech startup with operations in Seattle and Durham, N.C., has launched with $40 million in new funding and a leadership team peppered with veterans of Seattle cell therapy biotechs. Tune Therapeutic... |
| - | 9 top West Coast biotechs that VCs say are poised to take off in the next year | Tayfun Coskun/Anadolu Agency/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Insider asked 12 venture capitalists which biotech startups would take off in the next 12 months.... |
| - | Tune Therapeutics | “Tune Therapeutics aims to bring gene, cell, and regenerative therapies into a new era of human medicine – expanding their range of application to common, chronic and age-related diseases that are straining healthcare systems and limiting h... |
Show more